Leah G. Helton

Leah G. Helton

Auto-generated profile, based on publicly available information

Leah G. Helton

Athira Pharma, Inc., Bothell, WA USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
PPPragya Pathak
Pragya Pathak
KAKrista K. Alexander
Krista K. Alexander
LHLeah G. Helton
Leah G. Helton
MKMichalis Kentros
Michalis Kentros
TLTimothy J. LeClair
Timothy J. LeClair
EKEileen J. Kennedy
Eileen J. Kennedy
Missense mutations along the leucine-rich repeat kinase 2 (LRRK2) protein are a major contributor to Parkinson's Disease (PD), the second most commonly occurring neurodegenerative disorder worldwide. We recently reported the development of allosteric constrained peptide inhibitors that target and downregulate LRRK2 activity through disruption of LRRK2 dimerization. In this study, we designed doubly constrained peptides with the objective of inhibiting C-terminal of Roc (COR)-COR mediated dimerization at the LRRK2 dimer interface. We show that the doubly constrained peptides are cell-permeant, bind wild-type and pathogenic LRRK2, inhibit LRRK2 dimerization and kinase activity, and inhibit LRRK2-mediated neuronal apoptosis, and in contrast to ATP-competitive LRRK2 kinase inhibitors, they do not induce the mislocalization of LRRK2 to skein-like structures in cells. This work highlights the significance of COR-mediated dimerization in LRRK2 activity while also highlighting the use of doubly constrained peptides to stabilize discrete secondary structural folds within a peptide sequence.

15 July 2020
Verified
Book Chapter
Closed access
PDF file
LHLeah G. Helton
Leah G. Helton
ALAmeya J. Limaye
Ameya J. Limaye
GBGeorge N. Bendzunas
George N. Bendzunas
EKEileen J. Kennedy
Eileen J. Kennedy

11 December 2021 in Peptide Science
Verified
Journal Article
Closed access
PDF file
LHLeah G. Helton
Leah G. Helton
HRHardy Rideout
Hardy Rideout
FHFriedrich W. Herberg
Friedrich W. Herberg
EKEileen J. Kennedy
Eileen J. Kennedy

25 December 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
SRSherif Reda
Sherif Reda
WWWei Wu
Wei Wu
LHLeah Helton
Leah Helton
RTRobert W Taylor
Robert W Taylor
JJJewel L Johnston
Jewel L Johnston
KCKevin J. Church
Kevin J. Church
Background: Positive modulation of the hepatocyte growth factor (HGF)/MET system may represent a promising therapeutic strategy for Alzheimer’s disease (AD). Downstream effectors of HGF/MET, such as AKT or ERK, have been shown to activate pro‐survival signaling cascades that counteract pathological components of AD including excitotoxicity, mitochondrial dysfunction, oxidative stress, and protein aggregation. We have previously that fosgonimeton, a small molecule positive modulator of the HGF/MET system, elicits broad neuroprotective effects (Johnston et. al, 2022). Herein, we investigate the mechanism of action by which fosgonimeton induces neuroprotective effects in beta‐amyloid and glutamate‐challenged primary cortical neurons.Method: Primary rat cortical neurons were treated with the active metabolite of fosgonimeton (fosgo‐AM), challenged with beta‐amyloid (Aβ1‐42; 15 µM) for 24 hours, and co‐immunostained for microtubule‐associated protein‐2 (MAP‐2) and phospho‐tau (AT100). Immunofluorescence analyses were used to determine neuronal survival, neurite network integrity (total neurite length), and phospho‐tau levels. In a separate model, rat cortical neurons were treated with fosgo‐AM and challenged with glutamate (20 µM) for 24 hours, and immunostained for MAP‐2 to determine neuronal survival and neurite network. To elucidate the mechanism of neuroprotection, protein analyses via western blot and homogenous time‐resolved fluorescence were conducted to assay HGF/MET downstream signaling pathways. In addition, the effect of fosgo‐AM on mitochondrial membrane potential (MMP) was assessed in primary cortical neuron culture via fluorescent MMP dye.Result: Fosgo‐AM treatment significantly improved survival of cortical neurons, protected neurite networks, and reduced tau hyperphosphorylation after injury with Aβ1‐42. Additionally, fosgo‐AM reduced glutamate‐mediated cortical neuron death and neurite degeneration. Analyses of downstream signaling effects indicate that the neuroprotective effects of fosgo‐AM treatment may, in part, be the result of activation of AKT signaling and subsequent rescue of mitochondrial membrane potential, thereby reducing protein pathology and oxidative stress.Conclusion: Our in vitro data demonstrate the address pathological of AD reduce tau . neuroprotective effects of fosgonimeton, in addition to its neurotrophic and pro‐cognitive effects in preclinical models, highlight its therapeutic potential to interrupt disease progression and restore neuronal health. Fosgonimeton is currently in clinical for mild‐to‐moderate AD (NCT04488419; NCT04886063).